方法证据记录
Phase I Clinical Trial
A Phase I clinical trial is the first stage of human testing for a new drug, biologic, or intervention. Its primary objective is to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) rather than therapeutic efficacy. Small cohorts of participants — typically healthy volunteers or patients with advanced disease — receive sequentially increasing doses to identify the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) that define the boundary for subsequent trials.
源记录
引文逐字复制自方法源记录。这些引文不代表任何层级的验证。
Phase I Clinical Trial (First-in-Human / Dose-Escalation Study)
分类方法记录 · process-pipeline / epidemiology
- Storer, B. E. (1989). Design and analysis of phase I clinical trials. Biometrics, 45(3), 925–937. · DOI 10.2307/2531693
- International Council for Harmonisation (ICH). (2016). ICH E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). ICH Harmonised Guideline. · URL
精选声明
声明已持久化到证据分类账中，每个声明都有自己的评估。
尚无精选声明
当分类账中没有声明时，此视图不会自行创建声明评估。
相关方法
从方法图中生成，显示为机器建议的关系 — 不推断任何证据声明。